Evaluation of human P-glycoprotein (MDR1/ABCB1) ATPase activity assay method by comparing with in vitro transport measurements:: Michaelis-Menten kinetic analysis to estimate the affinity of P-glycoprotein to drugs

被引:26
|
作者
Shirasaka, Yoshiyuki
Onishi, Yuko
Sakurai, Aki
Nakagawa, Hiroshi
Ishikawa, Toshihisa
Yamashita, Shinji
机构
[1] Setsunan Univ, Fac Pharmaceut Sci, Hirakata, Osaka 5730101, Japan
[2] Tokyo Inst Technol, Dept Biomol Engn, Grad Sch Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan
关键词
P-glycoprotein; ATPase activity; Sf9 insect cell; high throughput; multidrug resistance (MDR1); ABCB1;
D O I
10.1248/bpb.29.2465
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Human ABC transporter P-glycoprotein (P-gp/ABCB1) encoded by the multidrug resistance (MDR1) gene is recognized as one of the most important factors regulating pharmacokinetics of a number of clinically important drugs because of its function of extruding a wide range of structurally unrelated amphiphilic and hydrophobic drugs from the inside to the outside of cells in an ATP-driven mechanism. In the present study, we have evaluated the high-speed ATPase activity assay method by comparing with in vitro transport assay systems using MDR1-transfected MDR1-MDCK cells. Since substrate drugs were found to interfere with the photometric detection of inorganic phosphate (Pi) that was liberated according to the hydrolysis of ATP to ADP in ATPase activity assay, at first, a method in which the amount of Pi can be calculated correctly. Results demonstrate that the kinetic parameters obtained in ATPase activity assay are not necessarily correspond with those in in vitro transport assay, suggesting that these methods might detect the different processes of drug-P-gp interaction. The combining of the ATPase activity assay and in vitro transport technologies provides us the insight into mechanisms of the membrane transport of drugs by P-gp.
引用
收藏
页码:2465 / 2471
页数:7
相关论文
共 50 条
  • [31] Association between 8 P-glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug-induced hyperprolactinaemia
    Geers, Lisanne M.
    Pozhidaev, Ivan, V
    Ivanova, Svetlana A.
    Freidin, Maxim B.
    Schmidt, Amand F.
    Cohen, Dan
    Boiko, Anastasiia S.
    Paderina, Diana Z.
    Fedorenko, Olga Yu
    Semke, Arkadiy, V
    Bokhan, Nikolay A.
    Wilffert, Bob
    Kosterink, Jos G. W.
    Touw, Daan J.
    Loonen, Anton J. M.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (09) : 1827 - 1835
  • [32] P-Glycoprotein (ABCB1/MDR1) Controls Brain Penetration and Intestinal Disposition of the PARP1/2 Inhibitor Niraparib
    Martins, Margarida L. F.
    Loos, Nancy H. C.
    Mucuk, Sumeyra
    de Jong, Danielle
    Lebre, Maria C.
    Rosing, Hilde
    Tibben, Matthijs
    Beijnen, Jos H.
    Schinkel, Alfred H.
    MOLECULAR PHARMACEUTICS, 2021, 18 (12) : 4371 - 4384
  • [33] EFFECTS OF CHEMICAL MOIETIES AND POLYMORPHISMS IN THE HUMAN ABC TRANSPORTER ABCB1 (P-GLYCOPROTEIN/MDR1) IN DRUG-INDUCED LIVER INJURY
    Ulzurrun, E.
    Crespo, E.
    Ruiz-Cabello, F.
    Stephens, C.
    Borraz, Y.
    Robles, M.
    Cabello, M. R.
    Fernandez, M. C.
    Pelaez, G.
    Romero-Gomez, M.
    Navarro, J. M.
    Planas, R.
    Salmeron, J. F.
    Guarner, C.
    Castiella, A.
    Lucena, M. I.
    Andrade, R. J.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S275 - S275
  • [34] Evidence for the critical role of transmembrane helices 1 and 7 in substrate transport by human P-glycoprotein (ABCB1)
    Sajid, Andaleeb
    Lusvarghi, Sabrina
    Chufan, Eduardo E.
    Ambudkar, Suresh, V
    PLOS ONE, 2018, 13 (09):
  • [35] Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer
    Wong, M
    Evans, S
    Rivory, LP
    Hoskins, JM
    Mann, GJ
    Farlow, D
    Clarke, CL
    Balleine, RL
    Gurney, H
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (01) : 33 - 42
  • [36] Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1). I. Preclinical aspects
    Aszalos, Adorjan
    DRUG DISCOVERY TODAY, 2007, 12 (19-20) : 833 - 837
  • [37] Quantitative structure-activity relationship analysis and molecular dynamics simulation to functionally validate nonsynonymous polymorphisms of human ABC transporter ABCB1 (P-glycoprotein/MDR1)
    Sakurai, Aki
    Onishi, Yuko
    Hirano, Hiroyuki
    Seigneuret, Michel
    Obanayama, Kazuya
    Kim, Gunwoo
    Liew, Ei Leen
    Sakaeda, Toshiyuki
    Yoshiura, Koh-ichiro
    Niikawa, Norio
    Sakurai, Minoru
    Ishikawa, Toshihisa
    BIOCHEMISTRY, 2007, 46 (26) : 7678 - 7693
  • [38] Impact of ABCB1 (MDR1) gene polymorphism and P-glycoprotein inhibitors on digoxin serum concentration in congestive heart failure patients
    Kurzawski, Mateusz
    Bartnicka, Lilianna
    Florczak, Marcin
    Gornik, Wanda
    Drozdzik, Marek
    PHARMACOLOGICAL REPORTS, 2007, 59 (01) : 107 - 111
  • [39] Effect of the G2677a/t polymorphism in the multidrug resistance 1 gene (MDR1, ABCB1) on P-glycoprotein (P-gp) expression in human placenta
    Abdel-Rahman, Sherif
    Nanovskaya, Tatiana
    Hankins, Gary On.
    Ahmed, Mahmoud
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2007, 197 (06) : S172 - S172
  • [40] Expression and activity of P-glycoprotein (MDR1/ABCB1) in peripheral blood mononuclear cells from patients with anorexia nervosa compared with healthy controls
    Storch, Caroline Henrike
    Nikendei, Christoph
    Schild, Sandra
    Haefeli, Walter Emil
    Weiss, Johanna
    Herzog, Wolfgang
    INTERNATIONAL JOURNAL OF EATING DISORDERS, 2008, 41 (05) : 432 - 438